Lipocine (NASDAQ:LPCN) Announces Quarterly Earnings Results, Beats Estimates By $0.26 EPS

Lipocine (NASDAQ:LPCN) issued its quarterly earnings data on Monday. The specialty pharmaceutical company reported ($0.34) EPS for the quarter, topping analysts’ consensus estimates of ($0.60) by $0.26, FiscalAI reports. The company had revenue of $1.15 million during the quarter, compared to the consensus estimate of $0.12 million. Lipocine had a negative net margin of 126.67% and a negative return on equity of 30.65%.

Lipocine Stock Performance

LPCN traded up $0.25 during trading on Wednesday, hitting $8.36. The stock had a trading volume of 15,638 shares, compared to its average volume of 134,445. The company has a market capitalization of $46.41 million, a PE ratio of -8.20 and a beta of 0.98. Lipocine has a twelve month low of $2.52 and a twelve month high of $12.37. The stock has a 50 day simple moving average of $9.08 and a two-hundred day simple moving average of $5.26.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in LPCN. Jane Street Group LLC acquired a new position in Lipocine during the 4th quarter valued at about $85,000. Citadel Advisors LLC acquired a new stake in Lipocine in the third quarter worth about $41,000. Renaissance Technologies LLC grew its stake in shares of Lipocine by 3.6% during the fourth quarter. Renaissance Technologies LLC now owns 37,397 shares of the specialty pharmaceutical company’s stock worth $300,000 after acquiring an additional 1,300 shares during the last quarter. Boothbay Fund Management LLC purchased a new stake in shares of Lipocine during the fourth quarter worth about $441,000. Finally, Geode Capital Management LLC increased its holdings in shares of Lipocine by 2.2% during the fourth quarter. Geode Capital Management LLC now owns 62,450 shares of the specialty pharmaceutical company’s stock valued at $502,000 after acquiring an additional 1,374 shares in the last quarter. 9.11% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several analysts have issued reports on LPCN shares. Wall Street Zen raised Lipocine from a “sell” rating to a “hold” rating in a research report on Sunday, February 15th. Weiss Ratings reissued a “sell (d-)” rating on shares of Lipocine in a research report on Monday, December 29th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $15.00 price objective (up from $7.00) on shares of Lipocine in a research report on Wednesday, January 21st. One analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Lipocine presently has a consensus rating of “Moderate Buy” and an average price target of $15.00.

Lipocine Company Profile

Lipocine Inc is a clinical-stage pharmaceutical company focused on the development and commercialization of oral drug delivery technologies. The company’s core expertise lies in lipid-based formulations designed to improve the bioavailability of therapeutics that traditionally require injectable administration. By leveraging proprietary technologies, Lipocine aims to offer patient-friendly alternatives with the potential for more consistent pharmacokinetic profiles and improved compliance.

The company’s lead product, TLANDO (LPCN 1021), is an oral testosterone replacement therapy approved by the U.S.